Phathom Pharmaceuticals (PHAT) Operating Income: 2022-2025
Historic Operating Income for Phathom Pharmaceuticals (PHAT) over the last 4 years, with Sep 2025 value amounting to -$15.3 million.
- Phathom Pharmaceuticals' Operating Income rose 78.43% to -$15.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.5 million, marking a year-over-year increase of 25.86%. This contributed to the annual value of -$277.5 million for FY2024, which is 65.84% down from last year.
- According to the latest figures from Q3 2025, Phathom Pharmaceuticals' Operating Income is -$15.3 million, which was up 74.52% from -$59.9 million recorded in Q2 2025.
- In the past 5 years, Phathom Pharmaceuticals' Operating Income ranged from a high of -$15.3 million in Q3 2025 and a low of -$78.9 million during Q1 2025.
- Over the past 3 years, Phathom Pharmaceuticals' median Operating Income value was -$59.9 million (recorded in 2025), while the average stood at -$54.4 million.
- Per our database at Business Quant, Phathom Pharmaceuticals' Operating Income crashed by 143.84% in 2024 and then soared by 78.43% in 2025.
- Phathom Pharmaceuticals' Operating Income (Quarterly) stood at -$46.6 million in 2022, then tumbled by 49.81% to -$69.9 million in 2023, then rose by 14.97% to -$59.4 million in 2024, then surged by 78.43% to -$15.3 million in 2025.
- Its Operating Income was -$15.3 million in Q3 2025, compared to -$59.9 million in Q2 2025 and -$78.9 million in Q1 2025.